Ardelyx Inc at Jefferies Healthcare Conference Transcript
Good morning. Welcome to the Jefferies 2023 Healthcare Conference. My name is Dennis Ding. I'm biotech analyst at Jefferies. And I had the pleasure of having the Ardelyx team here this morning to talk about all the great progress that they've made over the years.
I know it's been kind of a bumpy road over the last couple of years around XPHOZAH, but you guys have seemingly navigated that pretty well. And you guys have obviously some great updates throughout the year. And you guys are also launching an IBS drug as well.
So maybe before we really start, maybe you can just rightside us -- rightsize us in terms of your progress this year and where you see this year going.
Dennis, thank you and the entire Jefferies team for having us here. Looking at where we have navigated over these last 12 months, and certainly even longer than that, is to be here, now with about a year of launch experience under our belts with Ibsrela when we had to pivot to it with the unexpected
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
